top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
BRM962
Breast cancer tissue array containing 12 cases of paired normal and primary, and 36 cases of primary and metastatic tumors (in lymph nodes) from the same patients in duplicates, 96 cores, set 2, non-overlapping with BRM961, with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$475
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
TNM Classification: Breast carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
T1 - Tumor 2 cm or less in greatest dimension
T2 - Tumor more than 2 cm but not more than 5 cm in greatest dimension
T3 - Tumor more than 5 cm in greasiest dimension
T4 - Tumor of any size with direct extension to chest wall or skin
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Metastasis to movable ipsilateral lymph node(s)
N2 - Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
N3 - Metastasis to ipsilateral internal mammary lymph node(s)
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
Human
48
96
1.5mm
4um
8
12
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for comparative IHC or ISH based protein or RNA tissue profiling in paired normal breast, primary and metastatic tumor tissues from multiple breast cancer patients.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | F | 44 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
A02 | F | 62 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
A03 | F | 36 | Breast | Invasive ductal carcinoma | II | T3N0M0 | |
A04 | F | 48 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
A05 | F | 51 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
A06 | F | 45 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
A07 | F | 48 | Breast | Invasive ductal carcinoma | II | T2N2M0 | |
A08 | F | 32 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
A09 | F | 42 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
A10 | F | 38 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
A11 | F | 44 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
A12 | F | 42 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
B01 | F | 44 | Breast | Uninvolved breast tissue of A01 | |||
B02 | F | 62 | Breast | Uninvolved breast tissue of A02 | |||
B03 | F | 36 | Breast | Uninvolved breast tissue of A03 | |||
B04 | F | 48 | Breast | Uninvolved breast tissue of A04 | |||
B05 | F | 51 | Breast | Uninvolved breast tissue of A05 | |||
B06 | F | 45 | Breast | Uninvolved breast tissue of A06 | |||
B07 | F | 48 | Breast | Uninvolved breast tissue of A07 | |||
B08 | F | 32 | Breast | Uninvolved breast tissue of A08 | |||
B09 | F | 42 | Breast | Uninvolved breast tissue of A09 | |||
B10 | F | 38 | Breast | Uninvolved breast tissue of A10 | |||
B11 | F | 44 | Breast | Uninvolved breast tissue of A11 | |||
B12 | F | 42 | Breast | Uninvolved breast tissue of A12 | |||
C01 | F | 55 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
C02 | F | 50 | Breast | Invasive ductal carcinoma | II | T2N2M0 | |
C03 | F | 60 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
C04 | F | 58 | Breast | Invasive lobular carcinoma | II | T1N1M0 | |
C05 | F | 52 | Breast | Invasive ductal carcinoma | II | T4N2M0 | |
C06 | F | 30 | Breast | Invasive lobular carcinoma | II | T2N1M0 | |
C07 | F | 40 | Breast | Invasive ductal carcinoma | I | T2N1M0 | |
C08 | F | 64 | Breast | Invasive ductal carcinoma | I | T2N1M0 | |
C09 | F | 42 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
C10 | F | 38 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
C11 | F | 60 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
C12 | F | 65 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
D01 | F | 55 | Lymph node | Lymph node metastasis of C01 | |||
D02 | F | 50 | Lymph node | Lymph node metastasis of C02 | |||
D03 | F | 61 | Lymph node | Lymph node metastasis of C03 | |||
D04 | F | 58 | Lymph node | Lymph node metastasis of C04 | |||
D05 | F | 52 | Lymph node | Lymph node metastasis of C05 | |||
D06 | F | 30 | Lymph node | Lymph node metastasis of C06 | |||
D07 | F | 40 | Lymph node | Lymph node metastasis of C07 | |||
D08 | F | 64 | Lymph node | Lymph node metastasis of C08 | |||
D09 | F | 42 | Lymph node | Lymph node metastasis of C09 | |||
D10 | F | 38 | Lymph node | Lymph node metastasis of C10 | |||
D11 | F | 60 | Lymph node | Lymph node metastasis of C11 | |||
D12 | F | 65 | Lymph node | Lymph node metastasis of C12 | |||
E01 | F | 51 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E02 | F | 42 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
E03 | F | 37 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E04 | F | 55 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
E05 | F | 36 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E06 | F | 46 | Breast | Invasive ductal carcinoma | I | T2N1M0 | |
E07 | F | 47 | Breast | Invasive ductal carcinoma | II | T2N2M0 | |
E08 | F | 47 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E09 | F | 53 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
E10 | F | 62 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E11 | F | 47 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
E12 | F | 45 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
F01 | F | 51 | Lymph node | Lymph node metastasis of E01 | |||
F02 | F | 42 | Lymph node | Lymph node metastasis of E02 | |||
F03 | F | 37 | Lymph node | Lymph node metastasis of E03 | |||
F04 | F | 55 | Lymph node | Lymph node metastasis of E04 | |||
F05 | F | 36 | Lymph node | Lymph node metastasis of E05 | |||
F06 | F | 46 | Lymph node | Lymph node metastasis of E06 | |||
F07 | F | 47 | Lymph node | Lymph node metastasis of E07 | |||
F08 | F | 47 | Lymph node | Lymph node metastasis of E08 | |||
F09 | F | 53 | Lymph node | Lymph node metastasis of E09 | |||
F10 | F | 62 | Lymph node | Lymph node metastasis of E10 | |||
F11 | F | 47 | Lymph node | Lymph node metastasis of E11 | |||
F12 | F | 45 | Lymph node | Lymph node metastasis of E12 | |||
G01 | F | 49 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
G02 | F | 48 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G03 | F | 49 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
G04 | F | 41 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G05 | F | 43 | Breast | Invasive lobular carcinoma | T2N1M0 | ||
G06 | F | 42 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G07 | F | 55 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G08 | F | 60 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G09 | F | 45 | Breast | Invasive lobular carcinoma | II | T2N1M0 | |
G10 | F | 50 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G11 | F | 27 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G12 | F | 42 | Breast | Invasive lobular carcinoma | II | T2N1M0 | |
H01 | F | 49 | Lymph node | Lymph node metastasis of G01 | |||
H02 | F | 48 | Lymph node | Lymph node metastasis of G02 | |||
H03 | F | 49 | Lymph node | Lymph node metastasis of G03 | |||
H04 | F | 41 | Lymph node | Lymph node metastasis of G04 | |||
H05 | F | 43 | Lymph node | Lymph node metastasis of G05 | |||
H06 | F | 42 | Lymph node | Lymph node metastasis of G06 | |||
H07 | F | 55 | Lymph node | Lymph node metastasis of G07 | |||
H08 | F | 60 | Lymph node | Lymph node metastasis of G08 | |||
H09 | F | 45 | Lymph node | Lymph node metastasis of G09 | |||
H10 | F | 50 | Lymph node | Lymph node metastasis of G10 | |||
H11 | F | 27 | Lymph node | Lymph node metastasis of G11 | |||
H12 | F | 42 | Lymph node | Lymph node metastasis of G12 | |||
null |
bottom of page